<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0205851" disease_type="Neoplastic Process" abbrv="">Germ cell tumours</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GCTs</z:e>) of the central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) encompass various histological subtypes, and their optimal management has been the subject of debate </plain></SENT>
<SENT sid="1" pm="."><plain>To indicate a better management strategy for each subtype, we analysed the records of 111 patients (median age 14 years), who underwent treatment since 1970 </plain></SENT>
<SENT sid="2" pm="."><plain>With a median follow-up duration of 86 months, the probability of surviving 5 years was: 96% for pure <z:hpo ids='HP_0100620'>germinoma</z:hpo> patients, 100% for mature <z:hpo ids='HP_0009792'>teratoma</z:hpo>, 67% for immature <z:hpo ids='HP_0009792'>teratoma</z:hpo> and 69% immature <z:hpo ids='HP_0009792'>teratoma</z:hpo> mixed with <z:hpo ids='HP_0100620'>germinoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The probability of cause-specific progression of <z:hpo ids='HP_0100620'>germinomas</z:hpo> producing human chorionic gonadotropin (HCG) was higher than that of non-producing <z:hpo ids='HP_0100620'>germinomas</z:hpo> (P &lt; 0.01) </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GCTs</z:e> that included a highly malignant component, such as embryonal <z:mp ids='MP_0002038'>carcinoma</z:mp> or <z:e sem="disease" ids="C0014145" disease_type="Neoplastic Process" abbrv="">yolk sac tumour</z:e>, exhibited a poor prognosis with 38% chance of 5-year survival </plain></SENT>
<SENT sid="5" pm="."><plain>Late adverse effects of therapy included <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary malignancy</z:e> and cognitive, endocrinological, auditory and <z:e sem="disease" ids="C0042790" disease_type="Disease or Syndrome" abbrv="">visual dysfunctions</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Of 85 survivors with a median follow-up period of 99 months, 58 patients needed hormone replacement therapy, 26 patients showed poor performance status and, to date, only 1 patient has fathered children </plain></SENT>
<SENT sid="7" pm="."><plain>Because the outcomes varied widely for each subtype, the traditional categories, that is, <z:hpo ids='HP_0100620'>germinoma</z:hpo> and non-germinomatous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GCT</z:e> as an extrapolation from the gonadal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GCTs</z:e>, are not suitable for appropriately selecting therapeutic regimen for <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GCTs</z:e> </plain></SENT>
</text></document>